Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Pembrolizumab & Pancreatic Ductal Adenocarcinoma (PDAC) (Mismatch Repair Deficiency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI)), the FDA granted an accelerated, tissue‑agnostic approval for pembrolizumab for unresectable or metastatic MSI‑H or dMMR solid tumors (including Pancreatic Ductal Adenocarcinoma (PDAC) (Mismatch Repair Deficiency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI))) that have progressed after prior treatment and who have no satisfactory alternative treatment options, provided the biomarker status is confirmed by an FDA‑a…